Humuline 30/70 Patroon (Insulin Human)

Humuline 30/70 Patroon is indicated for the management of diabetes mellitus that requires both basal and mealtime insulin.

• Type 1 diabetes mellitus in adults and children who need a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus when oral agents and lifestyle measures do not achieve glycemic targets.
• Adjunct therapy during periods of increased insulin demand, such as illness, surgery, or pregnancy.
• Use in patients switching from separate regular and NPH insulin preparations to a combined formulation for convenience.
• Use in patients transitioning from insulin pump therapy to multiple daily injections.

• Humuline 30/70 Patroon contains two insulin species: regular (short‑acting) insulin and NPH (intermediate‑acting) insulin. Both bind to insulin receptors on muscle, adipose, and hepatic cells, activating the receptor’s intrinsic tyrosine‑kinase activity. This triggers downstream signaling through the PI3K‑Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis, reducing endogenous glucose production.

Adverse reactions to Humuline 30/70 Patroon are similar to other human insulin preparations and may involve local, metabolic, or hypersensitivity events.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection‑site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycemic control.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions ranging from urticaria to anaphylaxis.
• Lipodystrophy or lipoatrophy at repeated injection sites.
• Edema or fluid retention, particularly in patients with cardiac or renal impairment.

When prescribing Humuline 30/70 Patroon, clinicians should consider several safety factors to minimize risk and ensure appropriate use.

• Monitor blood glucose closely during initiation and dose adjustments to avoid hypoglycemia.
• Adjust doses in renal or hepatic impairment, as insulin clearance may be reduced.
• Educate patients on proper injection technique and site rotation to prevent lipodystrophy.
• Use caution in pregnant or breastfeeding women; insulin requirements may change rapidly.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Consider cardiovascular status, as fluid retention can exacerbate heart failure.

Humuline 30/70 Patroon can interact with other medicines that affect glucose metabolism or insulin action, requiring dose modifications or monitoring.

Avoid

• Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unrecognized low blood glucose.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that potentiate insulin effects.
• Corticosteroids, which raise blood glucose and may necessitate higher insulin doses.
• Thiazide diuretics, which can impair glucose tolerance.
• Alcohol, especially in excess, as it can cause delayed hypoglycemia.